Glioma treatment using Checkpoint inhibition + CAR looks promising!By Paul Everson / August 9, 2022 CD133 specific CAR-macrophages created in situ using NanoPorter hydrogel in combination with CD47 checkpoint blocking antibody improves post operative Glioblastoma survival in a humanized mouse model “Intracavity generation of glioma stem cell–specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy” Chen Chen, Xinyi Jiang, et al. Science Translational Medicine 14: 656 DOI: 10.1126/scitranslmed.abn1128 CD47 blocking mAb has Previously shown to be effective in treating patient Glioma: Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells Lif F, Jiang X, et al. (2017) Oncoimmunology 7(2): e1391973. doi: 10.1080/2162402X.2017.1391973. Related Ancell Human Products anti-CD47 mAb Products anti-CD133 mAb Products
